Literature DB >> 19264632

Peptide inhibitors of hepatitis C virus core oligomerization and virus production.

S Kota1, C Coito1, G Mousseau1, J-P Lavergne2, A D Strosberg1.   

Abstract

Hepatitis C virus (HCV) nucleocapsid assembly requires dimerization of the core protein, an essential step in the formation of the virus particle. We developed a novel quantitative assay for monitoring this protein-protein interaction, with the goal of identifying inhibitors of core dimerization that might block HCV production in infected Huh-7.5 hepatoma cells. Two core-derived, 18-residue peptides were found that inhibited the dimerization of a fragment of core comprising residues 1-106 (core106) by 68 and 63%, respectively. A third, related 15-residue peptide displayed 50% inhibition, with an IC50 of 21.9 microM. This peptide was shown, by fluorescence polarization, to bind directly to core106 with a Kd of 1.9 microM and was displaced by the unlabelled peptide with an IC50 of 18.7 microM. When measured by surface plasmon resonance, the same peptide bound core169 with a Kd of 7.2 microM. When added to HCV-infected cells, each of the three peptides blocked release, but not replication, of infectious virus. When measured by real-time RT-PCR, the RNA levels were reduced by 7-fold. The 15-residue peptide had no effect on HIV propagation. Such inhibitors may constitute useful tools to investigate the role of core dimerization in the virus cycle.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19264632     DOI: 10.1099/vir.0.008565-0

Source DB:  PubMed          Journal:  J Gen Virol        ISSN: 0022-1317            Impact factor:   3.891


  10 in total

1.  Liver-targeted antiviral peptide nanocomplexes as potential anti-HCV therapeutics.

Authors:  Jinjin Zhang; Jered C Garrison; Larisa Y Poluektova; Tatiana K Bronich; Natalia A Osna
Journal:  Biomaterials       Date:  2015-08-08       Impact factor: 12.479

2.  New small molecule inhibitors of hepatitis C virus.

Authors:  Wanguo Wei; Cuifang Cai; Smitha Kota; Virginia Takahashi; Feng Ni; A Donny Strosberg; John K Snyder
Journal:  Bioorg Med Chem Lett       Date:  2009-10-21       Impact factor: 2.823

3.  A time-resolved fluorescence-resonance energy transfer assay for identifying inhibitors of hepatitis C virus core dimerization.

Authors:  Smitha Kota; Louis Scampavia; Timothy Spicer; Aaron B Beeler; Virginia Takahashi; John K Snyder; John A Porco; Peter Hodder; Arthur Donny Strosberg
Journal:  Assay Drug Dev Technol       Date:  2010-02       Impact factor: 1.738

4.  Dimerization-driven interaction of hepatitis C virus core protein with NS3 helicase.

Authors:  G Mousseau; S Kota; V Takahashi; D N Frick; A D Strosberg
Journal:  J Gen Virol       Date:  2010-09-29       Impact factor: 3.891

5.  Rationally designed interfacial peptides are efficient in vitro inhibitors of HIV-1 capsid assembly with antiviral activity.

Authors:  Rebeca Bocanegra; María Nevot; Rosa Doménech; Inmaculada López; Olga Abián; Alicia Rodríguez-Huete; Claudio N Cavasotto; Adrián Velázquez-Campoy; Javier Gómez; Miguel Ángel Martínez; José Luis Neira; Mauricio G Mateu
Journal:  PLoS One       Date:  2011-09-08       Impact factor: 3.240

6.  Core as a novel viral target for hepatitis C drugs.

Authors:  Arthur Donny Strosberg; Smitha Kota; Virginia Takahashi; John K Snyder; Guillaume Mousseau
Journal:  Viruses       Date:  2010-08-20       Impact factor: 5.818

7.  Direct binding of a hepatitis C virus inhibitor to the viral capsid protein.

Authors:  Smitha Kota; Virginia Takahashi; Feng Ni; John K Snyder; A Donny Strosberg
Journal:  PLoS One       Date:  2012-02-28       Impact factor: 3.240

Review 8.  Targeting the Virus Capsid as a Tool to Fight RNA Viruses.

Authors:  Lucie Hozáková; Barbora Vokatá; Tomáš Ruml; Pavel Ulbrich
Journal:  Viruses       Date:  2022-01-18       Impact factor: 5.048

9.  High-throughput screening and rapid inhibitor triage using an infectious chimeric Hepatitis C virus.

Authors:  Michael J Wichroski; Jie Fang; Betsy J Eggers; Ronald E Rose; Charles E Mazzucco; Kevin A Pokornowski; Carl J Baldick; Monique N Anthony; Craig J Dowling; Lauren E Barber; John E Leet; Brett R Beno; Samuel W Gerritz; Michele L Agler; Mark I Cockett; Daniel J Tenney
Journal:  PLoS One       Date:  2012-08-06       Impact factor: 3.240

10.  Human Transbodies to HCV NS3/4A Protease Inhibit Viral Replication and Restore Host Innate Immunity.

Authors:  Surasak Jittavisutthikul; Watee Seesuay; Jeeraphong Thanongsaksrikul; Kanyarat Thueng-In; Potjanee Srimanote; Rolf G Werner; Wanpen Chaicumpa
Journal:  Front Immunol       Date:  2016-08-26       Impact factor: 7.561

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.